Long-term disease control during TAS-102 therapy in the VI line treatment in a 73-year-old mCRC patient. A case report Case report

Article Sidebar

PDF


Published: Mar 31, 2020
DOI: https://doi.org/10.24292/01.OR.120260320
Keywords:
metastatic colorectal cancer, TAS-102, long-term response

Main Article Content

Piotr Skalij
1. Department of Oncology, Medical University of Bialystok, Poland. 2. Department of Oncology with Daytime Chemotherapy Unit, Bialystok Oncology Centre, Poland
Piotr Tokajuk
1. Department of Oncology, Medical University of Bialystok, Poland. 2. Department of Oncology with Daytime Chemotherapy Unit, Bialystok Oncology Centre, Poland
Stefan Jelski
Department of Radiology, Bialostockie Oncology Center
Marek Z. Wojtukiewicz
1. Department of Oncology, Medical University of Bialystok, Poland. 2. Department of Oncology with Daytime Chemotherapy Unit, Bialystok Oncology Centre, Poland

Abstract

A case of 73-year-old patient with metastatic colorectal cancer who underwent trifluridine/tipiracil therapy within the VI line was presented. Treatment with trifluridine/tipiracil allowed to achieve stabilization of the existing cancer for nearly 7 months.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Article Details

How to Cite
1.
Skalij P, Tokajuk P, Jelski S, Wojtukiewicz MZ. Long-term disease control during TAS-102 therapy in the VI line treatment in a 73-year-old mCRC patient. A case report. OncoReview [Internet]. 2020Mar.31 [cited 2024Nov.22];10(1(37):15-7. Available from: https://journalsmededu.pl/index.php/OncoReview/article/view/1077
Issue
Vol 10 No 1(37) (2020)
Section
CARDIO-ONCOLOGY
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Mayer RJ, Van Cutsem E, Falcone A et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015; 372(20): 1909-19.
2. Xu J, Kim TW, Shen L et al. Results of a randomized, double-blind, placebo-controlled, Phase III trial of trifluridine/tipiracil (TAS-102) monotherapy in Asian patients With previously treated metastatic colorectal cancer: the TERRA study. J Clin Oncol. 2018; 36(4): 350-8.
3. Kwakman JJM, Vink G, Vestjens JH et al. Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands. Int J Clin Oncol. 2018; 23: 482-9.
4. Cremolini C, Rossini D, Martinelli E et al. Trifluridine/tipiracil (TAS-102) in refractory metastatic colorectal cancer: a multicenter register in the frame of the Italian compassionate use program. Oncologist. 2018; 23: 1178-87.